Hasil Pencarian - Karl D Lewis

  • Menampilkan 1 - 12 hasil dari 12
Perbaiki Hasil
  1. 1
    Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again

    Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again oleh Christina M. Davis, Karl D. Lewis

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Therapeutic options in cutaneous melanoma: latest developments

    Therapeutic options in cutaneous melanoma: latest developments oleh Rodabe N. Amaria, Karl D. Lewis, Rene Gonzalez

    Diterbitkan 2011-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

    Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled a... oleh Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun, Brigitte Dréno

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

    Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial oleh Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report

    Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report oleh Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Correction: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

    Correction: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer oleh Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial

    Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial oleh Ketty Peris, Timothy J. Inocencio, Alexander J. Stratigos, Karl D. Lewis, Zeynep Eroglu, Anne Lynn S. Chang, Cristina Ivanescu, Aleksandar Sekulic, Matthew G. Fury, Chieh‐I Chen, Ruben G. W. Quek

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients

    IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients oleh Richard P. Tobin, Kimberly R. Jordan, Puja Kapoor, Eric Spongberg, Dana Davis, Victoria M. Vorwald, Kasey L. Couts, Dexiang Gao, Derek E. Smith, Jessica S. W. Borgers, Jessica S. W. Borgers, Steven Robinson, Carol Amato, Rene Gonzalez, Rene Gonzalez, Karl D. Lewis, Karl D. Lewis, William A. Robinson, William A. Robinson, Virginia F. Borges, Virginia F. Borges, Virginia F. Borges, Martin D. McCarter, Martin D. McCarter

    Diterbitkan 2019-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients

    Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients oleh Song Y. Park, MD, Candice Church, PhD, Nora A. Alexander, BS, Michi M. Shinohara, MD, Kelly G. Paulson, MD, PhD, Karl D. Lewis, MD, Nancy S. Lee, MD, Paul Nghiem, MD, PhD

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

    Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial oleh Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

    Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint... oleh Jessica C Hassel, James Larkin, Madan Jagasia, Harriet Kluger, Omid Hamid, Jeffrey Weber, Jason Chesney, Amod Sarnaik, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Karl D Lewis, Nikhil I Khushalani, Parameswaran Hari, Marlana Orloff, Mike Cusnir, Giao Q Phan, Andrew J S Furness, Michael E Egger, Friedrich Graf Finckenstein, Giri Sulur

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

    Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence oleh Omid Hamid, Brendan Curti, Craig L Slingluff, Mohammed Milhem, Jose Lutzky, Suthee Rapisuwon, Brian Gastman, Takami Sato, Marcus O Butler, Robert Andtbacka, Eddy Hsueh, Robert Weber, John Glaspy, Sekwon Jang, Sajeve Thomas, Karl D Lewis, Leonel Hernandez-Aya, John Hyngstrom, Adam Berger, Edward Levine, Montaser F Shaheen, Vinay Gupta, Svetomir N Markovic, Tawnya Bowles, Joel Claveau, Prejesh Philips, Shernan G Holtan, William Schmidt, Juan Paramo, Arvinda Padmanabhan, Daniel Milton, Andrew Pecora, Suprith Badarinath, John Keech, Sujith Kalmadi, Pallavi Kumar, Anna Bar, J Thaddeus Beck, Jeffrey B Travers, Catalin Mihalcioiu, Peter Beitsch, Edward C McCarron, Deepti Behl, Brent Blumenstein, Joanna J Peterkin

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: